Sanofi has announced that SAR442168 will be evaluated in four Phase 3 clinical trials in participants with relapsing and progressive forms of multiple sclerosis. Subject to the satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in the fourth quarter of 2020.

"Principia's successful design and development of a whole portfolio of BTK inhibitors for immunology is aimed to transform the treatment for patients with immune-mediated diseases. The webcast, conference call details, and full presentation will be made available on Sanofi's Investor Relations webpage.

We are a global biopharmaceutical company focused on human health. Through Principia's proprietary Tailored Covalency® platform, our strategy is to build and advance a pipeline of best-in-class drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. Sanofi Investor Relations Contacts North America, Paul Laland, VP of Corporate Communications, Sanofi and Principia Forward-Looking Statements. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Sanofi and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. We are a global biopharmaceutical company focused on human health. Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective, Report Package: “Drug the Undruggable” Technologies, RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective, T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis, PipelineReview.com is powered by La Merie Business Intelligence, For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01, La Merie Publishing - Ulrich Martin | Carrer Garraf, 20, Bajos, 1a | 08870 Sitges | Spain T +49-7934-6839 668 | F +49-3212-1267 572 | Email This email address is being protected from spambots. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC's website at www.sec.gov. Being able to block or disrupt these signaling processes can help in stopping inflammation and tissue destruction related to autoimmune diseases and target some of the underlying pathophysiology. Both '168 and rilzabrutinib, have 'pipeline in a product' potential, and we look forward to unlocking their full treatment benefits across an array of diseases," said John Reed, M.D., Ph.D., Global Head of Research & Development at Sanofi. The rights of trade mark owners are acknowledged. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a global Phase 3 clinical trial in participants with pemphigus, a Phase 1/2 clinical trial in participants with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in participants with IgG4-Related Diseases and a Phase 3 trial in ITP. "The Phase 2b data in relapsing multiple sclerosis showed the strong potential of '168 to address disability and disease progression, and triggered the start of Phase 3 studies across the full spectrum of MS. * Further strengthens core R&D areas of autoimmune and allergic diseases, * Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments, * Allows expansion of SAR442168 development program into other central nervous system diseases and therapeutic areas, * Adds clinically advanced oral BTK inhibitor rilzabrutinib with potential across a range of immunology and inflammation indications, complementing Sanofi's existing R&D pipeline. PARIS, France and SOUTH SAN FRANCISCO, CA, USA I August 17, 2020 I Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which … The optimized target residence time has potential to deliver a desired efficacy with a stronger safety profile.

The webcast, conference call details, and full presentation will be made available on Sanofi's Investor Relations webpage. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. PARIS, France and SOUTH SAN FRANCISCO, CA, USA I August 17, 2020 I Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). document.getElementById('cloak31930').innerHTML = '';

Sanofi's and Principia's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov, Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY), View original content:http://www.prnewswire.com/news-releases/sanofi-to-acquire-principia-biopharma-301112953.html, Company Codes: NASDAQ-NMS:SNY, EuronextParis:SAN, NASDAQ-NMS:PRNB, © 1985 - 2020 BioSpace.com.

The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the "SEC") and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2019, and the current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K filed by Principia with the SEC. Through Principia's proprietary Tailored Covalency ® platform, our strategy is to build and advance a pipeline of best-in-class drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. Principia also has a topical BTK inhibitor, PRN473, which is in phase 1 development for immune diseases that could benefit from local application to the skin.

Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug candidates. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. The Sanofi and Principia Boards of Directors unanimously approved the transaction. This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug candidates. Principia Biopharma to Present at the 2020 Bank of America Health Care Conference 03/10/20 Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results Evercore is acting as financial advisor to Sanofi and Weil, Gotshal & Manges LLP is acting as its legal counsel. PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 /PRNewswire/ -- Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Sanofi and Principia do not undertake any obligation to update or revise any forward-looking information or statements.

The tender offer for the outstanding shares of Principia common stock referenced in this press release has not yet commenced. The Principia BTK inhibitor franchise is based on its proprietary Tailored Covalency® platform that has generated potential best-in-class clinical candidates. Additional Information for US shareholders. PRN473 Topical, a topical reversible covalent BTK inhibitor designed for immune-mediated diseases that could benefit from localized application to the skin, is being evaluated in Phase 1 trials. As part of the deal, Sanofi will gain access to Principia’s portfolio of Bruton tyrosine kinase (BTK) inhibitors for the treatment of autoimmune diseases. The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Principia common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. PRN2246/SAR442168 is a covalent BTK inhibitor which crosses the blood-brain barrier and is licensed to Sanofi. CEO Paul Hudson, who was appointed to the role in June last year, has already acquired the oncology firm Synthorx and last month signed a potential $2 billion collaboration with Kymera Therapeutics to develop immune-inflammatory drugs. The French pharma said it will pay $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors.

Full ownership of our brain-penetrant BTK inhibitor '168 removes complexities for this priority development program and simplifies future commercialization.". addy31930 = addy31930 + 'lamerie' + '.' + 'com'; Principia's Bruton tyrosine kinase (BTK) inhibitors add to Sanofi's efforts to accelerate and build a portfolio of the next generation of transformative treatments for autoimmune diseases. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The deal follows Sanofi’s announcement late last year that it is rethinking its R&D operations, turning its back on diabetes and focusing on badly needed “transformative” therapies and maximising the potential of its asthma and eczema drug Dupixent. The tender offer is expected to commence later this month. You need JavaScript enabled to view it. Any material effect of COVID-19 on any of the foregoing could also adversely impact Sanofi and Principia. "The addition of multiple BTK inhibitors to our pipeline demonstrates our commitment to strategic product acquisitions in our priority therapeutic areas.